NCT02043301View on ClinicalTrials.gov

Pharmacokinetics And Relative Bioavailability Of Bococizumab (PF-04950615; RN316) When Administered To The Abdomen, Thigh Or Upper Arm

PHASE1CompletedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

November 30, 2014

Study Completion Date

November 30, 2014

Conditions
Hypercholesterolemia
Interventions
BIOLOGICAL

Bococizumab (PF-04950615; RN316)

Single 150 mg PF-04950615 dose administered SC to the abdomen

BIOLOGICAL

Bococizumab (PF-04950615; RN316)

Single 150 mg PF-04950615 dose administered SC to the upper arm

BIOLOGICAL

Bococizumab (PF-04950615; RN316)

Single 150 mg PF-04950615 dose administered SC to the thigh

Trial Locations (6)

33143

Miami Research Associates, South Miami

MRA Clinical Research, LLC, South Miami

66211

Vince & Associates Clinical Research, Inc., Overland Park

66212

Vince & Associates Clinical Research, Inc., Overland Park

78229

Clinical Trials of Texas, Inc., San Antonio

92801

Anaheim Clinical Trials, LLC, Anaheim

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT02043301 - Pharmacokinetics And Relative Bioavailability Of Bococizumab (PF-04950615; RN316) When Administered To The Abdomen, Thigh Or Upper Arm | Biotech Hunter | Biotech Hunter